Literature DB >> 7662482

Slipped capital femoral epiphysis during treatment with recombinant human growth hormone for Turner syndrome.

S Sakano1, Y Yoshihashi, T Miura.   

Abstract

Recombinant human growth hormone has recently been used to treat the short stature of Turner syndrome. However, this therapy may induce slipped capital femoral epiphysis, since the epiphyseal plate widens and becomes weak through either growth hormone or hypogonadism. This report shows that a slipped capital femoral epiphysis occurred during this treatment for an 11-year-old girl who was suffering from Turner syndrome. Thus, these patients who are being treated with growth hormone should be carefully observed.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7662482     DOI: 10.1007/bf00444271

Source DB:  PubMed          Journal:  Arch Orthop Trauma Surg        ISSN: 0936-8051            Impact factor:   3.067


  9 in total

1.  Slipped capital femoral epiphysis during treatment with recombinant growth hormone for isolated, partial growth hormone deficiency.

Authors:  V Prasad; F Greig; W Bastian; S Castells; C Juan; T W AvRuskin
Journal:  J Pediatr       Date:  1990-03       Impact factor: 4.406

2.  Slipped upper femoral epiphysis following treatment with human growth hormone.

Authors:  M W Fidler; C G Brook
Journal:  J Bone Joint Surg Am       Date:  1974-12       Impact factor: 5.284

3.  Slipped femoral capital epiphysis occurring during growth hormone therapy. Report of a case.

Authors:  W Rennie; N Mitchell
Journal:  J Bone Joint Surg Br       Date:  1974-11

4.  The mechanical strength of the growth plate under the influence of sex hormones.

Authors:  M Oka; T Miki; H Hama; T Yamamuro
Journal:  Clin Orthop Relat Res       Date:  1979 Nov-Dec       Impact factor: 4.176

5.  Results from the first 2 years of a clinical trial with recombinant DNA-derived human growth hormone (somatrem) in Turner's syndrome.

Authors:  R G Rosenfeld; R L Hintz; A J Johanson; B Sherman
Journal:  Acta Paediatr Scand Suppl       Date:  1987

6.  Methionyl human growth hormone and oxandrolone in Turner syndrome: preliminary results of a prospective randomized trial.

Authors:  R G Rosenfeld; R L Hintz; A J Johanson; J A Brasel; S Burstein; S D Chernausek; T Clabots; J Frane; R W Gotlin; J Kuntze
Journal:  J Pediatr       Date:  1986-12       Impact factor: 4.406

7.  Slipped capital femoral epiphysis in growth hormone-deficient patients.

Authors:  E B Rappaport; D Fife
Journal:  Am J Dis Child       Date:  1985-04

8.  Treatment of Turner's syndrome with methionyl human growth hormone for six months.

Authors:  K Takano; N Hizuka; K Shizume
Journal:  Acta Endocrinol (Copenh)       Date:  1986-05

9.  Long term effects of human growth hormone on 1,959 patients with pituitary dwarfism throughout Japan.

Authors:  K Shizume
Journal:  Endocrinol Jpn       Date:  1984-04
  9 in total
  1 in total

1.  Limb lengthening in children with Russell-Silver syndrome: a comparison to other etiologies.

Authors:  V Goldman; T H McCoy; M D Harbison; A T Fragomen; S R Rozbruch
Journal:  J Child Orthop       Date:  2013-01-05       Impact factor: 1.548

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.